Abstracts tagged "pediatric rheumatology and pharmacokinetics"

Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].